Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics

SEONGNAM, South Korea, Aug. 23, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California.

Lilly Gateway Labs is a best-in-class innovation hub designed to empower biotechnology companies to advance groundbreaking science by providing access to wet lab facilities and opportunities to engage with Lilly scientists and executives. Lilly Gateway Labs is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities. 

Through its entry into Lilly Gateway Labs, Rznomics plans to accelerate candidate discovery and development across its target gene database bank comprising over 200 disease targets, while simultaneously driving long-term efforts to establish global clinical infrastructure for its lead pipelines, expand global strategic partnerships, and recruit top-tier R&D researchers in the U.S.

"Joining Lilly Gateway Labs in San Diego represents a meaningful milestone for Rznomics' proprietary RNA platform," said Seong-Wook Lee, CEO of Rznomics. "We intend to advance the development and commercialization of our RNA therapeutics by active collaboration with the global biotech ecosystem."

About Rznomics Inc.
Rznomics is a clinical-stage biopharmaceutical company based in South Korea focused on developing RNA-based gene therapies. The company's proprietary trans-splicing ribozyme platform enables precise RNA editing and has broad applicability across multiple indications. The company signed a research collaboration and license agreement with global pharmaceutical company Eli Lilly and Company in May 2025 for the development of a novel RNA editing therapeutic and listed on the KOSDAQ market in December 2025. (KOSDAQ 476830)

For more information, please visit www.rznomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rznomics-joins-lilly-gateway-labs-in-san-diego-to-accelerate-rna-therapeutics-302857887.html

SOURCE Rznomics